ASCO 2024

Prognostic value of ctDNA in therapeutic strategies; Endocrine therapy in ER-low BC

The search for predicitve biomarkers continues

Immunotherapy makes a difference in survival in eTNBC

AI for the prediction of disease progression

Adjuvant endocrine therapy for ER-low EBC

Avelumab in early TNBC

Personalized neoadjuvant therapy for high-risk breast cancer patients

ctDNA analysis in monarchE

Advantage for node-negative patients

ctDNA important for HR+ eBC?

Ribociclib is also effective in N0 HR+/HER2− EBC

Avelumab nel TNBC precoce

Improvement for firstline treatment for patients with endocrine resistance

Reassuring and clarifying new data for CDK4/6 inhibitors

Expanding T-DxD use to HER2 ultra-low - the success story continues

One step closer to chemo-free therapy for HR+/HER2+ patients

Responder premenopausal

Is there still a place for endocrine therapy in HER2+ BC

New data on the omission of chemotherapy in young patients

Leptomeningeal metastases in HER2+ mBC

Heterogenity of ER+ disease

Eribulin, Trastuzumab, Pertuzumab in 1stL HER2+ mBC

Systemic therapy of HER2+ patients with brain metastases

ER-low: endocrine therapy necessary after all?

Triple positive mBC - chemotherapy unnecessary?

T-DXD continues its impressive track record for MBC patients

The ADC revolution continues - ctDNA takes the next step in tumor characterization

HER2+ mBC 1stL T-Dxd

Novel ADC-ICI combination therapy

Ultra low - ultra good?

Broaden T-DXD as therapy standard for HER2low and ultra-low MBC

Sacituzumab tirumotecan - a new powerful ADC for advanced TNBC

Important OS benefit with T-Dxd in HER2+ mBC

Expanding use of T-DxD in HER2low and HER2 ultra-low MBC patients

Decreasing SG related toxicity with profilatic G-CFS

First-line inavolisib/placebo + palbociclib + fulvestrant preferred in patients with PIK3CA HR+ HER2- advanced breast cancer

Chemo-free, CDK4/6 inhibitor-based combination active in HR+/HER2+ PAM50-luminal advanced breast cancer

CDK4/6i effective in premenopausal patients as well

INAVO120 - updated results

CDK4/6 rechallenge

Endocrine therapy with Palbociclib + Trastuzumab

Chemo-free regimen in HER2+ luminal breast cancer

Already more in the 1stL?

Treatment beyond progression for CDK 4/6i

C'è ancora posto per la terapia endocrina nel BC HER2+?

INAVO120: risultati aggiornati

Importante beneficio en la supervivencia global con TDxD en el CMm HER2+

Sacituzumab tirumotecan – nowy aktywny koniugat w leczeniu zaawansowanego raka trójujemnego

Espansione dell'uso di T-DxD nelle pazienti con carcinoma mammario metastatico HER2-low e HER2 ultra-low

CDK4/6 rechallenge

La révolution de l'ADC se poursuit / ctDNA franchit une nouvelle étape dans la caractérisation des tumeurs

Disminución de la toxicidad relacionada con la OS con G-CSF y loperamide profiláctica

Leczenie bez chemioterapii, oparte na inhibitorze CDK4/6 aktywne w zaawansowanych rakach HR+/HER2+ o fenotypie luminalnym wg PAM50

Regime senza chemioterapia nel carcinoma mammario luminoso HER2+

Le traitement endocrinien a-t-il encore sa place dans la CB HER2+ ?

Is the metformin story over? How to treat HFNS symptomatology?

PSMA-PET CT: Ready for clinical practice or a PROMISE for the future?

Interesting data - but not practice changing

Focus on Quality of Life

ARASENS Post hoc analysis: Therapy after progression

mCRPC: Who benefits from which measures?

RCT in mCRPC

Exploring the CHAARTED TRIAL: Optimizing Treatment Strategies in Metastatic Prostate Cancer

Important QoL data

EMBARK: Quality of Life

The evolving role of PSMA-PET with new agents

Unlocking Insights: The ALLIANCE Trial redefining Prognostic Models in Metastatic Prostate Cancer

Unveiling the Potential: PSMA-PET in Prostate Cancer Staging - Insights from the PROMISE TRIAL

Deciphering EMBARK: Exploring Enzalutamide's Impact on Prostate Cancer Progression and Quality of Life

Radionukleotides - the next step forward

EMBARK demonstrates the importance of HRQoL benefit in both combination and monotherapy arms

mCRCP CYCLONE 2 study

EV-Pembro shows consistent outcome - caution with subset analyses

Perioperative treamtent in MIBC - new data for the use of sacituzumab govitecan

What to do with Cis Gem Nivo?

Biomarkers and long-term outcomes in pts with low tumor burden

ASCO 2024: Time for the rare GU tumors?

Treatment of urachal carcinoma

Preoperative use of sacituzumab govitecan

MI-UC - News from EVP standard

Quality of life not affected by i. v. Pembro

Modified FOLFIRINOX therapy as a good option for urachus carcinoma

Effect of an immune diet on the outcome after radical cystectomy

ctDNA as a biomarker in metastatic bladder cancer

ASCO24: Bladder cancer highlights

The Role of Topoisomerase Inhibitors in the preoperative setting of MIBC: The story has just begun

The future of sacituzumab govitecan

Interim analysis of the SURE-01/02 study

ASCO24: Bladder cancer highlights

Biomarcadores y resultados a largo plazo en pacientes con baja carga tumoral

El papel de los inhibidores de topoisomerasa en el contexto perioperatorio del cancer de vejiga musculo infiltrante: la historia acaba de empezar

El futuro de sacituzumab govitecan

ASCO 2024: momento para los tumores GU poco frequentes?

Supportive real-world data from German research platform CARAT

Evaluating risk criteria and monotherapy in mRCC

Advancing our understanding of biological mechanisms and the quest for the Ideal biomarker - Part 1

Advancing Our Understanding of Biological Mechanisms and the Quest for the Ideal Biomarker - Part 2

Combination is superior to monotherapy - how do we translate the results into clinical practice?

nccRCC

Belzutifan in earlier lines in advanced ccRCC

KIM-1: Will have a major impact

Another breakthrough perioperative

Metastasized chromophobe RCC

Combination therapies for chromophobe renal cell carcinoma are clearly superior

New IMDC risk group - very favorable

Adjuvant KIM-1 as prognostic & predictive biomarker

KIM-1 - old wine in new bottles

NIVO+CABO: significantly longer therapy-free time

Treatment of favorable prognosis mRCC patients: additional data to support treatment decisions

DFF332 a novel HIF inhibitor

The search of the ideal biomarker in advanced renal cell carcinoma: The Sisyphus myth?

Biomarker analysis of KN426 & CLEAR

New HIF inhibitor in clear cell RCC

The never ending saga of biomarkers

Tratamiento del cancer renal avanzado de pronostico favorable: datos adicionales para ayudar en la decision clinica

La busqueda del marcador ideal en el cancer renal avanzado: el mito de Sísifo?

Adjuvant therapy: how to identify patients who will benefit

End of the story in EGFRm disease?

Perioperative chemotherapy and N2 status

Gamechanger in EGFR-mutated NSCLC

4-year efficacy of Keynote-799 and ctDNA

Stadium III EGFR+: now permanently Osimertinib?!

4y follow-up of CheckMate 816

CheckMate 816: 4-year update

ctDNA predicts outcome in patients treated with osimertinib

Confirmed efficacy of periop IO in N2 R-NSCLC

Osimertinib improves PFS in stage III

Liquid biopsy in curative situation

Early change in SOC in EGFR+ LD-NSCLC

4y follow-up de CheckMate 816

Cambio temprano en el tratamiento estándar del EGFR+ LD-NSCLC

Le traitement adjuvant par osimertinib apres CTRT : changement de donne dans le cas du CBNPC muté EGFR

Lorlatinib with extraordinary data in ALK + NSCLC

TROP2-targeting ADCs: where a we heading?

Update for EGFR-positive NSCLC

KRAS in NSCLC - a lot to come

Confirmed efficacy of adagrasib in KRASG12C

EGFR+ NSCLC - amivantamab-based combination therapy

BAY2927088 - Promising Her2-Inhibitor in NSCLC

Adagrasib for KRASG12C mutation 2nd line

Subcut amivantamab - the future

Telehealth is just as effective as a face-to-face visit in early palliative care

KRAS building on single agent therapy

KRASG12C - the story continues

ALK+ NSCLC - CROWN revisited

Confirmed efficacy in PD-L1 negativity - CheckMate 9LA

ASCO 2024 highlights

ADCs - moving landscapes. Subgroups remain to be defined.

The end for local therapy for oligometastatic disease

Lorlatinib convincing in ALK mutation 1st line

Het einde van lokale therapie voor oligometastatische ziekte

La télésanté est aussi efficace qu'une consultation face a face dans les soins palliatifs précoces

ASCO 2024 highlights

BAY297088 - Inhibiteur Her2-Inhibitor dans le NSCLC

KRASG12C - het verhaal gaat verder

ASCO 2024 highlights

Redefining SOC in LD-SCLC: Durvalumab as consolidation therapy

Finally, change for LS-SCLC

Maintenance with durvalumab is the new SOC after chemo/radio therapy for LD-SCLC

LD-SCLC: What´s about PCI?

Tarlatamab shows activity in patients with brain metastasis

New SoC for LD-SCLC

Tot slot, verandering voor LS-SCLC

Le traitement d'entretien avec le durvalumab est le nouveau SOC après la chimio/radiothérapie pour le carcinomes à petites cellules en forme limitée

Unexpected results; which subgroup could benefit from atezolizumab?

Chemo-immuno in mesothelioma - update

Harsh to beat

Difícil de superar

Is the induction treatment the new strategy for selected patient group?

10 years follow up - immunotherapy for BRAF-mutated melanoma

Is adjuvant treatment still standard in macroscopic, resectable stage III melanoma?

Stimulating new combination of two antibody-cytokine fusions

Personalized mRNA-vaccination: Practice changer of the future?

Is the triplet ready for phase 3?

Longterm survival after adjuvant targeted therapy

Impactful studies from ASCO 24 I: NADINA

3-year update on mRNA vaccines in melanoma

Vaccine in combination with nivolumab for PDL1 resistance

New oncolytic immunotherapy (RP1) after PD-1 failure

TIL therapy for metastatic melanoma

Promising activity of brenetafusp in PD-L1 refractory melanoma

Neoadjuvant intratumoral therapy with Daromun in metastatic melanoma

Survival data for TT with dabrafenib and trametinib

A new triplet for metastatic melanoma

Triple checkpoint blockade - a new approach?

Intralesional therapy with Daromun

Adjuvant therapy with dabrafenib and trametinib - final results after 4 years

A new therapy benchmark for brain-met melanoma patients

Impactful studies from ASCO 24 III: Cell-therapy

Promising Results: Triple combination therapy in advanced melanoma

Neoadjuvant immunotherapy treatment for melanoma

Progress in neoadjuvant therapy with IO

Impactful studies from ASCO 24 II: Combi-AD

Identifying patients with longterm benefits during tebentafusp in mUM

Consolidation of the use of IO in clinically detectable stage III melanoma

No differences in PFS between the two study arms

Lentigo maligna therapy

mRNA vaccine plus pembrolizumab in adjuvant therapy

Emerging rescue therapies for PD1 refractory melanoma

No hubo diferencias en la PFS entre los dos brazos del estudio

Prometedora actividad de brenetafusp en melanoma refractario a PD-L1

Risultati promettenti: Tripla terapia di combinazione nel melanoma avanzato

Consolidación del uso de IO en melanoma en estadio III clínicamente detectable

Encouraging developmental IO-options

New therapeutic approaches: Get over PD1 resistances?

New MOA in r/m HNSCC

New insights in localized HNSCC

New perspectives in HPV+ r/m HNSCC

New idea: anti-digest for EC?

De-escalation in ovarian cancer?

Clear cell carcinomas benefit from IO therapy